The two anti-apoptotic proteins Bcl-2 and Bcl-xL, and the two pro-apoptotic proteins Bax and Bcl-xS were measured by Western blotting in 51 neoplastic and 8 normal endometrial samples. The corresponding mRNA levels were analyzed by semiquantitative reverse transcriptase-polymerase chain reaction in a subgroup of 19 endometrial carcinomas. Neoplastic tissues had higher amounts of Bcl-2 protein than normal tissues (p < 0.051). Bcl-xL followed the same trend since its levels were higher in tumor than in normal samples (p < 0.048). Interestingly, Bcl-2 and Bcl-xL protein content showed a trend towards an inverse correlation (r = 0.27, p < 0.052). mRNA and protein levels directly correlated only with Bcl-2 (r = 0.63, p < 0.0032). Despite the fact that the amounts of Bcl-2, Bax and Bcl-xL proteins in the neoplastic population were not significantly differently distributed according to the clinicopathological features of the patients, the differences observed between normal and neoplastic samples suggest that these proteins may play a role in endometrial carcinoma: long-term follow-up studies will be required to confirm this hypothesis.

Keywords:
Bcl-2 family, Western blot, Endometrium, Reverse transcriptase-polymerase chain reaction
1.
Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456–1462.
2.
Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, Finke J: Interleukin-10 increases bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 1996;88:2549–2558.
3.
Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121–139.
4.
Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB, Korsmeyer SJ: Multiple Bcl-2 family members demonstrate selective dimerization with Bax. Proc Natl Acad Sci USA 1995;92:7834–7838.
5.
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597–608.
6.
Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 1993;74:609–619.
7.
Nuñez G, London L, Hockenbery D, Alexander GM, McKearn JP: Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602–3610.
8.
Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D: Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991;51:6529–6538.
9.
Lu Q, Poulsom R, Wong L, Hanby AM: Bcl-2 expression in adult and embryonic non-hematopoietic tissues. J Pathol 1993;169:431–437.
10.
Cerroni L, Soyer HP, Kerl H: Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7–11.
11.
Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein, a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499–504.
12.
Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnhill MS, Pierce CB, Harris A, Gatter KC, Mason DY: Bcl-2 protein expression in non-small-cell lung carcinoma. N Engl J Med 1993;329:690–694.
13.
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J, Tu S, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940–6944.
14.
Bronner MP, Culin C, Reed JC, Furth EE: The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995;146:20–26.
15.
Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A, Benedetti-Panici P, Mancuso S: Bcl-2, bax, bcl-xl and bcl-xs expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998;4:517–524.
16.
Park JR: Cytokine regulation of apoptosis in hematopoietic precursors. Curr Opin Hematol 1996;3:191–196.
17.
Tao X, Tilly KI, Maravel DV, Shufren JL, Krajewski S, Reed JC, Tilly JL, Isaacson KB: Differential expression of members of the bcl-2 gene family in proliferative and secretory human endometrium: Glandular epithelial cell apoptosis is associated with increased expression of bax. J Clin Endocrinol Metab 1997;82:2738–2746.
18.
Chan HW, Mole MM, Levison DA, Ball RY, Lu Q, Patel K, Hanby AM: Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 1995;177:241–246.
19.
Saegusa M, Okayasu I: Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: Immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. Mod Pathol 1997;9:402–406.
20.
Taskin M, Lallas TA, Barber HRK, Shevchuk MM: Bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10:728–734.
21.
Petterson F: Annual Report on the Results of Treatment in Gynecological Cancer. Stockholm, FIGO, 1988.
22.
World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, WHO, 1979, pp 16–21.
23.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989.
24.
Chomczynski P, Sacchi N: Single step method of RNA isolation by guanidium-thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
25.
Wang TTY, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995;55:2487–2489.
26.
Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B: Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;60:854–859.
27.
Nuñez G, Clarke MF: The Bcl-2 family of proteins: Regulators of cell death survival. Trends Cell Biol 1994;4:399–403.
28.
Henderson SG, Brown KA, Perkins SL, Abbot TM, Clayton F: Bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol 1996;9:430–438.
29.
Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507–4511.
30.
Krajewska M, Krajewski S, Epstein JL, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567–1576.
31.
Chieng DC, Ross JS, Ambros RA: Bcl-2 expression and development of endometrial carcinoma. Mod Pathol 1996;9:402–406.
32.
Ioffe OB, Papadimitriou JC, Drachenberg CB: Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29:1150–1159.
33.
Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G, Reed JC: Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449–1457.
34.
White E: Life, death, and the pursuit of apoptosis. Genes Dev 1996;10:1–15.
35.
Park JR, Bernstein ID, Hockenbery DM: Primitive human hematopoietic precursors express bcl-x but not bcl-2. Blood 1995;86:868–876.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.